Back to today’s briefing

Story perspectives

Trump Policies Threaten U.S. Biopharma Innovation and Growth

5/11/2025

41 9

Summary

Story summary

Audrey Greenberg, CEO of AG Capital Advisors, warns that the Trump administration's policies are jeopardizing the biopharma sector. With FDA disruptions, NIH funding cuts, and unpredictable tariffs, companies are forced to navigate a turbulent landscape that stifles innovation and limits patient access. As a result, the U.S. may lose its biopharma edge, with firms eyeing stability in the UK and China.

History

Historical Context

The current challenges facing the U.S. biopharma sector echo the 1990s, when regulatory shifts and funding cuts threatened innovation. Back then, companies adapted to survive, leading to a boom in biotech. Today, similar pressures risk the U.S. losing its competitive edge, pushing firms to seek stability abroad.

1 of 2

Story summary

Audrey Greenberg, CEO of AG Capital Advisors, warns that the Trump administration's policies are jeopardizing the biopharma sector. With FDA disruptions, NIH funding cuts, and unpredictable tariffs, companies are forced to navigate a turbulent landscape that stifles innovation and limits patient access. As a result, the U.S. may lose its biopharma edge, with firms eyeing stability in the UK and China.

1 / 2